Skip to main content

Research Repository

Advanced Search

The effect of chemotherapy on health-related quality of life in mesothelioma: Results from the SWAMP trial

Arnold, D. T.; Hooper, C. E.; Morley, A.; White, P.; Lyburn, I. D.; Searle, J.; Darby, M.; Hall, T.; Hall, D.; Rahman, N. M.; De Winton, E.; Clive, A.; Masani, V.; Dangoor, A.; Guglani, S.; Jankowska, P.; Lowndes, S. A.; Harvey, J. E.; Braybrooke, J. P.; Maskell, Nick A

The effect of chemotherapy on health-related quality of life in mesothelioma: Results from the SWAMP trial Thumbnail


Authors

D. T. Arnold

C. E. Hooper

A. Morley

Paul White Paul.White@uwe.ac.uk
Professor in Applied Statistics

I. D. Lyburn

J. Searle

M. Darby

T. Hall

D. Hall

N. M. Rahman

E. De Winton

A. Clive

V. Masani

A. Dangoor

S. Guglani

P. Jankowska

S. A. Lowndes

J. E. Harvey

J. P. Braybrooke

Nick A Maskell



Abstract

© 2015 Cancer Research UK. All rights reserved. Background: The effect of chemotherapy on health-related quality of life (HRQoL) in malignant pleural mesothelioma (MPM) is poorly understood. Patient-individualised prognostication and prediction of treatment response from chemotherapy is useful but little evidence exists to guide practice. Method: Consecutive patients with MPM who were fit for first-line chemotherapy with pemetrexed and cisplatin\carboplatin were recruited and followed up for a minimum of 12 months. This study focussed on the HRQoL outcomes of these patients using the EQ-5D, EORTC QLQ-C30 and LC13. Results: Seventy-three patients were recruited of which 58 received chemotherapy and 15 opted for best supportive care (BSC). Compliance with HRQoL questionnaires was 98% at baseline. The chemotherapy group maintained HRQoL compared with the BSC group whose overall HRQoL fell (P=0.006) with worsening dyspnoea and pain. The impact of chemotherapy was irrespective of histological subtype although those with non-epithelioid disease had worse HRQoL at later time points (P=0.012). Additionally, those with a falling mesothelin or improvement on modified-RECIST CT at early follow-up had a better HRQoL at 16 weeks. Conclusions: HRQoL was maintained following chemotherapy compared with a self-selected BSC group. Once chemotherapy is initiated, a falling mesothelin or improved RECIST CT findings infer a quality-of-life advantage.

Citation

Arnold, D. T., Hooper, C. E., Morley, A., White, P., Lyburn, I. D., Searle, J., …Maskell, N. A. (2015). The effect of chemotherapy on health-related quality of life in mesothelioma: Results from the SWAMP trial. British Journal of Cancer, 112(7), 1183-1189. https://doi.org/10.1038/bjc.2015.77

Journal Article Type Article
Acceptance Date Feb 1, 2015
Online Publication Date Mar 10, 2015
Publication Date Mar 31, 2015
Deposit Date Aug 3, 2015
Publicly Available Date Feb 22, 2016
Journal British Journal of Cancer
Print ISSN 0007-0920
Electronic ISSN 1532-1827
Publisher Springer Nature [academic journals on nature.com]
Peer Reviewed Peer Reviewed
Volume 112
Issue 7
Pages 1183-1189
DOI https://doi.org/10.1038/bjc.2015.77
Keywords mesothelioma, chemotherapy, quality of life
Public URL https://uwe-repository.worktribe.com/output/840692
Publisher URL http://dx.doi.org/10.1038/bjc.2015.77